GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) are contraindicated during breastfeeding per UK Summary of Product Characteristics No weight loss injection currently has regulatory approval for use whilst breastfeeding in the UK Transfer into breast milk and effects on nursing infants remain unknown due to absence of human studies Appetite suppression from these medications may compromise maternal nutrition needed for adequate milk production Safe alternatives include gradual dietary modification, regular physical activity, and NHS weight management programmes Women should defer weight loss medications until breastfeeding is completed and seek GP advice for postpartum weight concerns Table of Contents Weight Loss Injections and Breastfeeding: Key Safety Considerations Types of Weight Loss Injections and Their Use During Lactation Potential Risks to Breastfed Infants Alternative Approaches to Postpartum Weight Management When to Seek Medical Advice About Weight Loss While Breastfeeding Scientific References Frequently Asked Questions Weight Loss Injections and Breastfeeding: Key Safety Considerations Weight loss injections, particularly GLP-1 receptor agonists such as semaglutide (Wegovy) and liraglutide (Saxenda), have become increasingly popular for weight management
Semaglutide's original potency masked these signals, but as receptor sensitivity drops, ghrelin's effect becomes more noticeable
The active ingredient may not be what you think it is Some compounded GLP-1 products use what's called a salt form of the active ingredient, like "semaglutide sodium" or "semaglutide acetate." These are not the same chemical entity as the FDA-approved semaglutide base used in Ozempic and Wegovy
Beans and legumes : Lentils, chickpeas, kidney beans, and other legumes are great sources of non-heme iron
